Background: Genomic basis of drug response is the main objective of Pharmacogenomic
studies. The classical paradigm of clinical treatment focused in the disease is
becoming a new approach, the Personalized Medicine (PM) based on the individual patient.
One important challenge of PM application is the availability of adequate and validated
Objective: In this review, we will focus on the impact of new technologies on Pharmacogenomics,
the most recent advances to be applied to Personalized Medicine and how they
contribute to face arising challenges related to quality aspects, clinical validation, cost and
Method: Current situation of new methodologies such as single cell sequencing, long
fragment reads or nanopore systems is reviewed using Pubmed in order to explore the scientific
literature and to assess their contribution to boost the translation from basic pharmacogenomics
to clinical practice.
Results: An overview of the most recent technological advances to be applied to pharmacogenomics
is provided, including a discussion about advantages and disadvantages of the
Conclusion: The great development of new technologies can open promising insight on
pharmacogenomics, allowing to study genes involved in pharmacokinetics and pharmacodynamics
and providing holistic information of drug toxicity and efficacy. The understanding
of therapeutic effects, adverse events and drugs interaction is still limited by incomplete
knowledge of cellular pathways, therefore inferring interacting biological molecules
involved in drug response is required.